KDM6A mutations have been confirmed in corresponding patient samples 16, 17, for example, over 30% of bladder cancers contain KDM6A mutations and these mutations also occur to a lesser extent in hematological malignancies including acute lymphoblastic leukemia (subtypes of T-cell and B-cell ALL) along with chronic myelomonocytic leukemia (CMML) 18, 19. This evidence concerns the gene KDM6A and urinary bladder carcinoma.